Development Pipeline

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s cancers by cancer type. In addition to leveraging our internal research resources, we continually evaluate external pre-clinical and early-stage assets that might expand our pipeline and contribute to our durable competitive advantages.

Filter by:
Molecule/Asset
Indication(s)
Phase

Safety and efficacy have not been established for investigational products and/or uses.

1L, first line; 2L, second line; 3L, third line; ADC, antibody-drug conjugate; BC, breast cancer; AML, acute myeloid leukemia; BCL2, B-cell lymphoma 2; BP-ALL, B-cell precursor acute lymphoblastic leukemia; BsAb, bispecific antibody; BTC, biliary tract cancer; BTK, Bruton tyrosine kinase; CCR8, the C-C motif chemokine receptor 8; CD3, cluster of differentiation 3; CD19, cluster of differentiation 19; CD79B, cluster of differentiation 79B; CDAC, chimeric degradation activating compound; CDK, cyclin-dependent kinase; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; DGKζ, diacylglycerol kinase ζ; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FL, follicular lymphoma; gBRCAm, germilin BRCA mutation; GC, gastric cancer; GEA, gastroesophageal adenocarcinomas; GEJC, gastroesophageal junction carcinoma; GI, gastrointestinal; GnRH, gonadotropin-releasing hormone; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; LA, locally advanced; LAG3, lymphocyte activation gene 3; LS-SCLC, limited-stage small cell lung cancer; mBC, metastatic breast cancer; MCL, mantle cell lymphoma; mCRPC, metastatic castration-resistant prostate cancer; MDS, myelodysplastic syndromes; MM, multiple myeloma; MSS, microsatellite stability; MTx, maintenance treatment; MZL, marginal zone lymphoma; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non–small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; P13kδ, phosphoinositide 3-kinase-δ; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PSOC, platinum-sensitive ovarian cancer; RCC, renal cell carcinoma; R/R, recurrent/refractory; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; SMAC, second mitochondria-derived activator of caspase; Sq, squamous; STEAP1, six-transmembrane epithelial antigen of the prostate 1; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIM3, T-cell immunoglobulin domain and mucin domain 3; TN, treatment naive; UBC, urothelial bladder cancer; UC, urothelial carcinoma; WM, Waldenström macroglobulinemia.

aMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.
bin combination with Zanubrutinib.
1Ensem collaboration; BeiGene has global rights.
2DualityBio collaboration; BeiGene has global rights.
3Leads Biolabs collaboration; BeiGene has ex-China commercial rights.
4Zymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights.
5Amgen collaboration; BeiGene has China commercial rights.
6Luye collaboration; BeiGene has China rights.

Pipeline Highlights

For additional clinical trial information please visit clinicaltrials.gov.

Anti-OX40 (BGB-A445),
Agonist Monoclonal Antibody
CDK4 Inhibitor (BGB-43395)
Pamiparib (BGB-290),
a PARP1 and PARP2 inhibitor

Ociperlimab (BGB-A1217),
a TIGIT inhibitor